AI Specialist Council
Structured, evidence-grounded reasoning across all cases reviewed by the specialist agent council.
Chest pain with rising troponin — evolving NSTEMI workup
Four specialist agents reviewed this case. Cardiology and Evidence & Guidelines agents concur that the biomarker and ECG pattern supports an early invasive strategy consistent with NSTE-ACS guidance. Pharmacology confirms current therapy is appropriate. Critical Care notes haemodynamics remain within tolerable range, creating a mild difference in urgency framing that the treating physician should reconcile with direct examination.
Acute stroke — thrombolysis and post-treatment monitoring
Neurology and Radiology agents concur that thrombolysis was appropriately administered within the eligible window based on imaging and clinical timeline. Pharmacology has abstained from recommending a precise anticoagulation resumption time, citing insufficient post-treatment imaging data. Critical Care flags a rising blood pressure trend approaching, but not yet exceeding, the post-thrombolysis management threshold.
Septic shock with early deterioration signals
Critical Care and Infectious Disease agents independently flag concerning trends — deteriorating haemodynamics and persistently rising CRP — that together suggest the current source-control and antimicrobial strategy may be insufficient. Nephrology and Pharmacology confirm renal dosing has been appropriately adjusted. This is a case with multimodal conflict between the expected treatment response and the observed clinical trajectory.
AKI on CKD — medication-related contributor
All three invoked agents are in full agreement: the combination of self-directed NSAID use and background ACE-inhibitor therapy is the most probable contributor to this AKI episode, and current management (discontinuation of both agents, supportive care) is guideline-concordant. No disagreement identified in this case.
New breast cancer diagnosis — staging and biomarker-directed planning
Radiology and Pathology agents show strong concordance confirming invasive ductal carcinoma with a BI-RADS 5 correlate. Oncology and Evidence & Guidelines agents agree the PIK3CA mutation supports consideration of targeted combination therapy pending multidisciplinary review. The BRCA2 variant remains of uncertain significance — the Pathology agent has explicitly abstained from asserting its relevance until germline testing is complete.